| Drug General Information |
| Drug ID |
D0NX0M
|
| Former ID |
DNC006350
|
| Drug Name |
3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H15NO
|
| Canonical SMILES |
COC1=CC2=C(C=C1)C=C(CC2)C3=CN=CC=C3
|
| InChI |
1S/C16H15NO/c1-18-16-7-6-12-9-13(4-5-14(12)10-16)15-3-2-8-17-11-15/h2-3,6-11H,4-5H2,1H3
|
| InChIKey |
WUTGTMFGCHNUET-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 19 |
Target Info |
Inhibitor |
[1]
|
|---|
| Cytochrome P450 11B1, mitochondrial |
Target Info |
Inhibitor |
[2]
|
| 17 alpha-hydroxylase-C17, 20-lyase |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Superpathway of steroid hormone biosynthesis
|
|
Estradiol biosynthesis II
|
|
Estradiol biosynthesis IPWY-7305:Superpathway of steroid hormone biosynthesis
|
|
Glucocorticoid biosynthesis
|
|
Mineralocorticoid biosynthesisPWY-7305:Superpathway of steroid hormone biosynthesis
|
|
Androgen biosynthesis
|
|
KEGG Pathway
|
Steroid hormone biosynthesis
|
|
Metabolic pathways
|
|
Ovarian steroidogenesishsa00140:Steroid hormone biosynthesis
|
|
Metabolic pathwayshsa00140:Steroid hormone biosynthesis
|
|
Ovarian steroidogenesis
|
|
Prolactin signaling pathway
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
PANTHER Pathway
|
Androgen/estrogene/progesterone biosynthesis
|
|
PathWhiz Pathway
|
Androgen and Estrogen MetabolismPW000141:SteroidogenesisPW000045:Androgen and Estrogen Metabolism
|
|
Steroidogenesis
|
|
Reactome
|
Endogenous sterolsR-HSA-194002:Glucocorticoid biosynthesis
|
|
Endogenous sterolsR-HSA-193048:Androgen biosynthesis
|
|
Glucocorticoid biosynthesis
|
|
Endogenous sterols
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Tryptophan metabolism
|
|
Oxidation by Cytochrome P450
|
|
Ovarian Infertility Genes
|
|
Metabolism of steroid hormones and vitamin D
|
|
FSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation
|
|
Corticotropin-releasing hormoneWP702:Metapathway biotransformation
|
|
Steroid Biosynthesis
|
|
Glucocorticoid & Mineralcorticoid Metabolism
|
|
Prostate Cancer
|
|
Phase 1 - Functionalization of compounds
|
| References |
| REF 1 | J Med Chem. 2006 Apr 6;49(7):2222-31.Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. |
|---|
| REF 2 | J Med Chem. 2008 Aug 28;51(16):5064-74. Epub 2008 Aug 1.Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization onpotency and selectivity. |
|---|
